Literature DB >> 11315264

Are stable postoperative biliary atresia patients really stable?

H Kobayashi1, K Horikoshi, A Yamataka, G J Lane, A Furuhata, N Sueyoshi, T Miyano.   

Abstract

Transforming growth factor-beta 1 (TGF beta-1) is an important mediator of liver-cell proliferation and replication that is implicated in hepatic fibrosis (HF). Hepatic stellate cells (HSC) are activated by TGF beta-1 and are the main precursor cells involved in fibrogenesis. The correlation between serum TGF beta-1, activated HSC in liver-biopsy specimens, and liver biochemistry was investigated to determine the value of TGF beta-1 as an indicator of clinical status in postoperative biliary atresia (BA) patients. Thirty-two postoperative BA patients (mean age 11.2 +/- 2.8 years) and 13 normal controls (mean age 10.3 +/- 3.7 years) were studied. Based on average liver function test (LFT) results over a 3-month period immediately prior to this study, the BA patients were divided into group I (anicteric, normal LFT; n = 10); group II (anicteric, elevated liver transaminases; n = 12), and group III (jaundiced end-stage liver fibrosis awaiting liver transplantation; n = 10). Serum TGF beta-1 was determined using ELISA. Liver-biopsy specimens were examined with antibody against TGF beta-1 and alpha-smooth muscle actin (SMA) antibody for detection of activated HSC. Serum TGF beta-1 was significantly higher in groups I (11.4 +/- 3.7 ng/ml; P < 0.01) and II (23.3 +/- 11.3 ng/ml; P < 0.001) than in group III (3.0 +/- 1.5 ng/ml) and controls (4.5 +/- 2.5 ng/ml) despite normal LFT in group I. The 3 subjects with the highest serum TGF beta-1 in group II had bile lakes. Biopsies from groups I and II were strongly positive for TGF beta-1 in hepatocytes and Kupffer cells and for activated HSC detected by SMA compared with group III and controls. Because serum TGF beta-1 and activated HSC are only present during active fibrosis, we conclude that there is progressive fibrogenesis even in seemingly normal postoperative BA patients. In particular, bile lakes should be regarded as a key sign of progressive HF, the presence of which should be regarded with extreme caution. We suggest that serum TGF beta-1 could be used as an accurate indicator of progressive fibrogenesis in postoperative BA patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11315264     DOI: 10.1007/s003830000494

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  7 in total

1.  Comment on stable postoperative biliary patients.

Authors:  N P Sheth
Journal:  Pediatr Surg Int       Date:  2004-10       Impact factor: 1.827

2.  Association of circulating osteopontin levels with clinical outcomes in postoperative biliary atresia.

Authors:  Sittisak Honsawek; Paisarn Vejchapipat; Voranush Chongsrisawat; Nutchanart Thawornsuk; Yong Poovorawan
Journal:  Pediatr Surg Int       Date:  2010-11-03       Impact factor: 1.827

3.  The correlation between plasma cytokine levels in jaundice-free children with biliary atresia.

Authors:  Zhi-Hong Jian; Li-Ching Wang; Chieh-Chung Lin; Jiaan-Der Wang
Journal:  World J Pediatr       Date:  2015-04-06       Impact factor: 2.764

4.  Relationship between prognosis of biliary atresia and infection of cytomegalovirus.

Authors:  Chun Shen; Shan Zheng; Wei Wang; Xian-Min Xiao
Journal:  World J Pediatr       Date:  2008-05       Impact factor: 2.764

5.  Inchin-ko-to prevents medium-term liver fibrosis in postoperative biliary atresia patients.

Authors:  Tsuyoshi Tamura; Hiroyuki Kobayashi; Atsuyuki Yamataka; Geoffrey J Lane; Hiroyuki Koga; Takeshi Miyano
Journal:  Pediatr Surg Int       Date:  2007-02-08       Impact factor: 1.827

6.  Connective tissue growth factor and progressive fibrosis in biliary atresia.

Authors:  Hiroyuki Kobayashi; Nobukazu Hayashi; Kenji Hayashi; Atsuyuki Yamataka; Geoffrey J Lane; Takeshi Miyano
Journal:  Pediatr Surg Int       Date:  2005-01       Impact factor: 1.827

7.  Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis.

Authors:  Bin-Bin Zhang; Wei-Min Cai; Hong-Lei Weng; Zhong-Rong Hu; Jun Lu; Min Zheng; Rong-Hua Liu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.